98%
921
2 minutes
20
Melanoma is characterized by rapid growth and high invasiveness, resulting in an exceptionally high malignancy and a significant propensity for metastasis. Current therapeutic modalities, such as chemotherapy and radiotherapy, exhibit limited efficacy due to severe side effects and immunosuppressive effects. Consequently, the development of precise and effective integrated therapeutic strategies is of paramount importance. Here, we report a multifunctional and multienzyme active nanosystem (FeCP@PDA-GOx) that synergistically integrates starvation therapy, chemodynamic therapy, mild photothermal therapy (mPTT), and immunotherapy to achieve multidimensional therapeutic effects. This nanoplatform harnesses the enzymatic activities of glucose oxidase, peroxidase, oxidase, and catalase to enhance tumor microenvironment modulation and drug delivery efficiency, ultimately inducing ferroptosis in tumor cells. The system also establishes a positive feedback loop to further amplify its catalytic performance. Additionally, it effectively suppresses the expression of heat shock proteins in tumor cells, thereby augmenting the therapeutic efficacy of mPTT. Moreover, the system activates robust immune responses, suppressing lung metastasis and eliciting systemic antitumor effects to inhibit the growth of distal tumors. Experimental results demonstrate that this multifunctional nanoplatform exhibits exceptional therapeutic efficacy and safety in melanoma treatment, laying a solid foundation for the advancement of personalized medicine and intelligent therapeutic strategies.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12322653 | PMC |
http://dx.doi.org/10.1002/anie.202505911 | DOI Listing |
FEMS Microbiol Rev
September 2025
CIISA - Centre for Interdisciplinary Research in Animal Health, Faculty of Veterinary Medicine, University of Lisbon, Lisbon, Portugal.
African Swine Fever (ASF), caused by the highly contagious African swine fever virus (ASFV), poses a significant threat to domestic and wild pigs worldwide. Despite its limited host range and lack of zoonotic potential, ASF has severe socio-economic and environmental consequences. Current control strategies primarily rely on early detection and culling of infected animals, but these measures are insufficient given the rapid spread of the disease.
View Article and Find Full Text PDFClin Transl Sci
September 2025
Food and Drug Administration, Silver Spring, Maryland, USA.
Since the first decentralized clinical trial (DCT) was conducted in 2011, there has been an increased usage of DCT due to its benefits of patient-centricity and generalizability of findings. This trend was further expedited by the global COVID-19 pandemic. We identified 23 case studies across various therapeutic areas and grouped them into different categories according to their purposes-by necessity, for operational benefits, to address unique research questions, to validate innovative digital endpoints, or to validate decentralization as a clinical research platform.
View Article and Find Full Text PDFCell Mol Biol (Noisy-le-grand)
September 2025
Associate Professor, School of Pharmacy, Desh Bhagat University, Mandi Gobindgarh-Punjab 147301, India.
Alcoholic fatty liver disease (AFLD) is a leading cause of chronic liver disease worldwide, contributing to significant morbidity and mortality. Despite its growing prevalence, no FDA-approved pharmacological treatments exist, leaving lifestyle modifications as the primary intervention. AFLD pathogenesis involves a complex interplay of lipid accumulation, oxidative stress, insulin resistance, and inflammation, highlighting the need for innovative therapeutic approaches.
View Article and Find Full Text PDFBioDrugs
September 2025
Department of Nephrology, Instituto de Investigación Hospital "12 de Octubre" (imas12), Avda. De Córdoba s/n, 28041, Madrid, Spain.
Anti-CD20 monoclonal antibodies are gaining clinical relevance in the nephrology community due to their demonstrated efficacy and favorable safety profiles across short-, medium-, and long-term use. Initially developed for hematologic malignancies and multiple sclerosis, B-cell depletion therapies are now being investigated across a broader spectrum of autoimmune diseases, including glomerulopathies, both with and without associated podocytopathy. Recent advances have led to the development of novel anti-CD20 agents that are being used not only as potential alternatives to corticosteroids but also as adjunctive therapies in complex clinical settings.
View Article and Find Full Text PDFClin Rheumatol
September 2025
Department of Dermatology, the First Affiliated Hospital, Army Medical University, No. 29 Gaotanyan Street, Shapingba District, Chongqing, China.
Background: Plasmacytoid dendritic cells (pDCs) are a specialized subset of dendritic cells known for their ability to produce type I interferon (IFN I), contributing to antiviral defense and the pathogenesis of autoimmune diseases like systemic lupus erythematosus (SLE). In SLE patients, pDCs are excessively activated, leading to overproduction of IFN-α, which plays a critical role in disease progression. However, no bibliometric analysis has been conducted on the relationship between pDCs and SLE.
View Article and Find Full Text PDF